Botulinum toxin for chronic pain conditions

Botulinum neurotoxin (BoNT), derived from Clostridium botulinum, a Gram-positive anaerobic bacterium, was first used for therapeutic purposes in 1980 for treatment of strabismus. Since that time, its use has expanded for a multitude of cosmetic and therapeutic indications. There are seven BoNT serotypes of which there are currently four BoNT versions available in the United States, onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxin A (Xeomin), and rimabotulinumtoxinB (Myobloc).

Source: Disease a Month - July 13, 2016 Category: Infectious Diseases Authors: Rachel Kermen Source Type: research